BioMed Realty Trust, Inc. (NYSE:BMR)

CAPS Rating: 2 out of 5

The Company is a real estate investment trust, or REIT, focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry.

Results 1 - 10 of 10

Recs

0
Member Avatar T206 (72.73) Submitted: 7/22/2013 11:20:44 AM : Outperform Start Price: $20.36 BMR Score: -8.20

S

Recs

0
Member Avatar jaybird43 (42.34) Submitted: 5/19/2013 1:09:38 PM : Underperform Start Price: $21.24 BMR Score: +14.74

A P/E of 758? There has to be a better value out there somewhere and it should not be hard to find it. I understand that REITs pay very well, but some like this one will be found to be overvalued.

Recs

0
Member Avatar Gemini846 (50.38) Submitted: 8/30/2010 8:08:26 AM : Outperform Start Price: $14.07 BMR Score: -30.67

It's never too early to go Christmas shopping. Picking a broad basket of stocks that seem favorable when expecting a short term bull rally.

Recs

2
Member Avatar JakilaTheHun (99.93) Submitted: 12/23/2009 10:25:51 AM : Outperform Start Price: $5.20 BMR Score: +172.84

Note on this pick:

I bought in around $6.50. It was very obvious to me based on BMR's low amount of leverage, strong cash flows, and property portfolio that it was worth more than that.

As I write this, it sells at $16. I believe it is still slightly undervalued even at this price. Based on cash flows, equity interest in assets, and other factors, I'd value this company somewhere between $20 - $28, just based on a quick glance. I do, however, have some concerns about the locations of their properties (many being in bubble markets), so I'd probably stay on the conservative end of that.

I would not buy in at the current price. It's too expensive, in my view, when compared to other REITs. All the same, I plan on continuing my pick here on CAPS, especially since it pays out a sizable dividend. My strategy for CAPS on the REITs is buy-and-hold for life. If I see BMR tip over $25, I might consider ending my pick, but otherwise, I plan on keeping this pick forever.

Recs

1
Member Avatar puccini3005 (29.54) Submitted: 4/3/2009 2:48:07 AM : Outperform Start Price: $13.45 BMR Score: -43.65

BioMed Realty Trust is a relatively small REIT, specializing in the life science industry. An update - BMR now "owns or has interests in 69 properties, which include 112 buildings with approximately 10.4 million rentable square feet of laboratory and office space, including approximately 1.9 million square feet of development in progress...." (quote courtesy of the company home page).
I agree with the other bull pitchers that BMR is undervalued - great margins (profit and operating - 22% and 36% respectively), strong cash flow, and a low forward PE at 4.62.
The dividend is nice and fat too.
My timing was bad for when I bought my BMR shares, but even though the share price has gone down significantly, they have't yet decreased or suspended the dividend - they actually raised it a few times.

Recs

0
Member Avatar pslorenz (95.12) Submitted: 3/1/2009 4:41:56 PM : Outperform Start Price: $6.45 BMR Score: +65.90

I am jumping on this now as it looks way undervalued and it it positioned well in a still growing sector (given the current economy.) Govt spending may further add to the valueof this as thigs such as stem cell research get the funding green light again.

Recs

0
Member Avatar ErfanH (< 20) Submitted: 8/7/2007 12:56:31 PM : Outperform Start Price: $16.11 BMR Score: -4.34

Undervalued.

Recs

0
Member Avatar germey (47.04) Submitted: 5/1/2007 12:08:33 PM : Outperform Start Price: $19.38 BMR Score: -27.50

The Biotech industry will continue to be well funded an be a good tenant. The team leading this REIT has experience and a great track record.

Recs

0
Member Avatar EBITDA107 (56.04) Submitted: 3/11/2007 9:49:41 AM : Outperform Start Price: $17.86 BMR Score: -26.14

bio science office reits - -good niche

Recs

2
Member Avatar NetscribeREIT (< 20) Submitted: 2/16/2007 7:45:45 AM : Outperform Start Price: $20.65 BMR Score: -37.83

BioMed Realty Trust is a Real Estate Investment Trust (REIT) focused on providing real estate to the Life Science Industry. The company’s portfolio comprises of 56 properties, which include 92 buildings with around 7.9 million rentable square feet of laboratory and office space. The company’s properties are located in reputed markets like Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, New York and New Jersey.

The Life Science Industry is going through a bullish trend with the increase in number of aging U.S. population resulting from the transition of baby boomers to senior citizens. Moreover, Research and Development spending by U.S. Biopharmaceutical companies is at its peak with $55.2 billion. This bodes well with the company, as it particularly caters to biotechnology and pharmaceutical companies. To further strengthen its Boston position, the company has acquired Center for Life Science during the end of 2006.

The company’s revenue has almost doubled during the past one year, thanks to its continuous acquisition. To sustain this top-line growth, the company has recently acquired Lyme Properties remaining portfolio for $511 million. Further, during December 2006 the company bought ELDEC building, which includes additional land that can be used to accommodate new construction.

Health care spending in the U.S. has already surpassed $2 trillion mark in 2006. Factors like aging of the population and changes in medical technology would be a driving factor for health care industry. BioMed’s continuing spree of acquisition should enable the company to take advantage of this growth in Life Science Industry, which makes the stock more lucrative.

Results 1 - 10 of 10

Featured Broker Partners


Advertisement